Biodexa Pharmaceuticals (BDRX) Other Operating Expenses (2018 - 2021)

Biodexa Pharmaceuticals (BDRX) posted Other Operating Expenses of -$58358.4 for Q3 2021, down 247.32% sequentially from $39613.5 in Q4 2020.

Biodexa Pharmaceuticals (BDRX) Other Operating Expenses (2018 - 2021) Analysis & Trends

Biodexa Pharmaceuticals has reported Other Operating Expenses for 3 years, with the latest figure at -$58358.4 in Q3 2021.

Quarterly Other Operating Expenses changed N/A year-over-year to -$58358.4 in Q3 2021, while the trailing twelve-month figure through Sep 2022 was -$58358.4 (down 211.33% YoY) and the FY2020 annual result came in at -$290217.0, changed N/A from the prior year.
Other Operating Expenses slipped to -$58358.4 in Q3 2021 per BDRX's latest filing, from $39613.5 in the prior quarter.
Over five years, Other Operating Expenses peaked at $39613.5 in Q4 2020 and troughed at -$1.8 million in Q4 2018.
A 3-year average of -$609742.1 and a median of -$58358.4 in 2021 frame the typical range for Other Operating Expenses.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Biodexa Pharmaceuticals	63,168.17	-11.29 Mn	-

Download Data